We consider that the gradual nature of the reform provides a fairly protected environment for European manufacturers over the next four years, and we continue to believe that full deregulation in the EU market for sugar production and processing is remote.

The ratings reflect the group's excellent business position, based on high growth rates in its pharmaceuticals division, its global No.1 position as a provider of oncology drugs, well stocked late-stage pipeline, and conservative financial profile.